Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $21.00.

ARTV has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. HC Wainwright initiated coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 target price for the company.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $6.25 on Friday. The company’s 50 day moving average price is $10.39. Artiva Biotherapeutics has a 52-week low of $6.19 and a 52-week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). As a group, equities research analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $152,234,000. Franklin Resources Inc. purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $7,435,000. Geode Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $4,774,000. Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics during the third quarter valued at $4,506,000. Finally, Wellington Management Group LLP acquired a new position in Artiva Biotherapeutics during the third quarter valued at $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.